Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
Juan-Manuel SanchoBelén NavarroJoan Alfons Soler CamposJaime Pérez de OteyzaCristina de Barrenetxea LekueMarco BregniSilvina Grasso CicalaMario SpioneCristina MombiedroBegoña SolerPier Luigi ZinzaniPublished in: European journal of haematology (2020)
Pixantrone was effective and well tolerated in a real-world population of multiply R/R patients with aggressive B-cell NHL, many of whom had very poor prognostic factors.